Table 4.

Treatment-related AEs reported in ≥10% of all treated patients

	All treated patients (N=52)
	Any grade	Grade 3–4
Total patients with a treatment-related AE, n (%)	48 (92.3)	19 (36.5)
Treatment-related AEs in ≥10% of all treated patients, n (%)
Fatigue	25 (48.1)	2 (3.8)
Diarrhea	16 (30.8)	2 (3.8)
Nausea	14 (26.9)	0
Vomiting	10 (19.2)	0
Rash maculo-papular	9 (17.3)	3 (5.8)
Pruritus	9 (17.3)	0
Decreased appetite	9 (17.3)	0
Lipase increased	6 (11.5)	4 (7.7)
Muscular weakness	6 (11.5)	1 (1.9)
Pyrexia	6 (11.5)	0

Includes events reported between first dose and 100 days after last dose of study therapy.

AE, adverse event.